NCT00984386 is a Phase 2 clinical trial of Zesteem in Cicatrix, sponsored by Renovo.

Who is sponsoring NCT00984386?

NCT00984386 is sponsored by Renovo.

What drugs are being tested in NCT00984386?

Interventions in NCT00984386: Zesteem, Zesteem, Zesteem, Zesteem, Placebo.

What condition does NCT00984386 study?

NCT00984386 studies Cicatrix, Wound-healing.

Is NCT00984386 still recruiting?

NCT00984386 is currently completed. Last updated 24 September 2009.

Last reviewed 2009-09-24 · How we verify

NCT00984386

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Single Site, Placebo and Standard Care Controlled, Double Blind, Randomised Trial to Investigate the Efficacy of Four Doses of Zesteem in Accelerating Early Wound Healing of Punch Biopsy Skin Wounds.

Completed Phase 2 Last updated 24 September 2009

What this trial tests

Phase 2 trial testing Zesteem in Cicatrix in 44 participants. Completed in 1 April 2005.

Timeline

1 March 2005

Primary endpoint
1 April 2005

1 April 2005

Quick facts

Lead sponsor	Renovo
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	44
Start date	1 March 2005
Primary completion	1 April 2005
Estimated completion	1 April 2005
Sites	1 location across United Kingdom

Drugs / interventions tested

Zesteem — full drug profile →
Zesteem — full drug profile →
Zesteem — full drug profile →
Zesteem — full drug profile →
Placebo

Conditions studied

Cicatrix — all drugs for Cicatrix →
Wound-healing — all drugs for Wound-healing →

Sponsor

Renovo — full company profile →

Who can join

Adults 18 to 85, any sex, with Cicatrix or Wound-healing. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To assess acceleration of early wound healing in male and postmenopausal female subjects following administration of intradermal Zesteem. The primary trial endpoint will be the distance travelled by the epithelium over the biopsy site.
Time frame: Day 3

Sponsor's own description

The purpose of this study is to investigate early wound healing of one application of four different doses of intradermal Zesteem (17β-Estradiol) in male subjects and female subjects two years post-menopausal.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cicatrix

Currently open trials in the same condition.

NCT06122090 — Treatment of Hypopigmented Scars With Bimatoprost · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00984386 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Renovo
Last refreshed: 24 September 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00984386.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing